BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 30643192)

  • 1. Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers.
    Panagopoulou M; Karaglani M; Balgkouranidou I; Biziota E; Koukaki T; Karamitrousis E; Nena E; Tsamardinos I; Kolios G; Lianidou E; Kakolyris S; Chatzaki E
    Oncogene; 2019 May; 38(18):3387-3401. PubMed ID: 30643192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care.
    El Messaoudi S; Mouliere F; Du Manoir S; Bascoul-Mollevi C; Gillet B; Nouaille M; Fiess C; Crapez E; Bibeau F; Theillet C; Mazard T; Pezet D; Mathonnet M; Ychou M; Thierry AR
    Clin Cancer Res; 2016 Jun; 22(12):3067-77. PubMed ID: 26847055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
    Visvanathan K; Fackler MS; Zhang Z; Lopez-Bujanda ZA; Jeter SC; Sokoll LJ; Garrett-Mayer E; Cope LM; Umbricht CB; Euhus DM; Forero A; Storniolo AM; Nanda R; Lin NU; Carey LA; Ingle JN; Sukumar S; Wolff AC
    J Clin Oncol; 2017 Mar; 35(7):751-758. PubMed ID: 27870562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer.
    Kioulafa M; Kaklamanis L; Stathopoulos E; Mavroudis D; Georgoulias V; Lianidou ES
    Ann Oncol; 2009 Jun; 20(6):1020-5. PubMed ID: 19150938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
    Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
    Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer.
    Fu D; Ren C; Tan H; Wei J; Zhu Y; He C; Shao W; Zhang J
    Medicine (Baltimore); 2015 Mar; 94(11):e637. PubMed ID: 25789956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing.
    Li Z; Guo X; Tang L; Peng L; Chen M; Luo X; Wang S; Xiao Z; Deng Z; Dai L; Xia K; Wang J
    Tumour Biol; 2016 Oct; 37(10):13111-13119. PubMed ID: 27449045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival.
    Balgkouranidou I; Karayiannakis A; Matthaios D; Bolanaki H; Tripsianis G; Tentes AA; Lianidou E; Chatzaki E; Fiska A; Lambropoulou M; Kolios G; Kakolyris S
    Clin Chem Lab Med; 2013 Jul; 51(7):1505-10. PubMed ID: 23403728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.
    Gampenrieder SP; Rinnerthaler G; Hackl H; Pulverer W; Weinhaeusel A; Ilic S; Hufnagl C; Hauser-Kronberger C; Egle A; Risch A; Greil R
    Theranostics; 2018; 8(8):2278-2288. PubMed ID: 29721079
    [No Abstract]   [Full Text] [Related]  

  • 10. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
    Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
    Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer.
    Chimonidou M; Strati A; Malamos N; Georgoulias V; Lianidou ES
    Clin Chem; 2013 Jan; 59(1):270-9. PubMed ID: 23136251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
    Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.
    Fackler MJ; Lopez Bujanda Z; Umbricht C; Teo WW; Cho S; Zhang Z; Visvanathan K; Jeter S; Argani P; Wang C; Lyman JP; de Brot M; Ingle JN; Boughey J; McGuire K; King TA; Carey LA; Cope L; Wolff AC; Sukumar S
    Cancer Res; 2014 Apr; 74(8):2160-70. PubMed ID: 24737128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the circulating cell-free DNA marker association with diagnosis and prognostic prediction in patients with lymphoma: a single-center experience.
    Li M; Jia Y; Xu J; Cheng X; Xu C
    Ann Hematol; 2017 Aug; 96(8):1343-1351. PubMed ID: 28623396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients.
    de Vos L; Gevensleben H; Schröck A; Franzen A; Kristiansen G; Bootz F; Dietrich D
    Clin Epigenetics; 2017; 9():125. PubMed ID: 29213339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.
    Connolly RM; Fackler MJ; Zhang Z; Zhou XC; Goetz MP; Boughey JC; Walsh B; Carpenter JT; Storniolo AM; Watkins SP; Gabrielson EW; Stearns V; Sukumar S
    Breast Cancer Res Treat; 2018 Jan; 167(1):107-116. PubMed ID: 28918548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A seven-gene CpG-island methylation panel predicts breast cancer progression.
    Li Y; Melnikov AA; Levenson V; Guerra E; Simeone P; Alberti S; Deng Y
    BMC Cancer; 2015 May; 15():417. PubMed ID: 25986046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer.
    Vietsch EE; Graham GT; McCutcheon JN; Javaid A; Giaccone G; Marshall JL; Wellstein A
    Cancer Genet; 2017 Dec; 218-219():39-50. PubMed ID: 29153095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
    Ai B; Liu H; Huang Y; Peng P
    Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.